Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President and CEO

Vice President, Finance

Chief Operating Officer

Executive Chairperson

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of gene...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-25	Premium	bought	Premium	Premium	Premium	-
2024-03-25	Premium	bought	Premium	Premium	Premium	-
2024-03-22	Premium	bought	Premium	Premium	Premium	-
2023-09-29	Premium	bought	Premium	Premium	Premium	-
2023-08-29	Premium	bought	Premium	Premium	Premium	-
2023-08-29	Premium	bought	Premium	Premium	Premium	-
2023-08-28	Premium	bought	Premium	Premium	Premium	-
2022-12-20	Premium	bought	Premium	Premium	Premium	-
2022-12-20	Premium	bought	Premium	Premium	Premium	-
2022-12-20	Premium	bought	Premium	Premium	Premium	President and CEO
2022-12-19	Premium	bought	Premium	Premium	Premium	-
2022-12-19	Premium	bought	Premium	Premium	Premium	-
2022-12-19	Premium	bought	Premium	Premium	Premium	President and CEO
2022-12-16	Premium	bought	Premium	Premium	Premium	-
2022-12-16	Premium	bought	Premium	Premium	Premium	-
2022-12-09	Premium	bought	Premium	Premium	Premium	-
2022-03-22	Premium	sold	Premium	Premium	Premium	-
2022-03-21	Premium	sold	Premium	Premium	Premium	-
2022-03-21	Premium	bought	Premium	Premium	Premium	-
2022-03-18	Premium	sold	Premium	Premium	Premium	-
2022-03-16	Premium	acquired	Premium	Premium	Premium	-
2021-08-31	Premium	bought	Premium	Premium	Premium	-
2021-03-30	Premium	bought	Premium	Premium	Premium	Vice President, Finance
2021-03-30	Premium	bought	Premium	Premium	Premium	-
2021-03-30	Premium	acquired	Premium	Premium	Premium	-

DSGN - Design Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for DSGN